In dealing with this kind of disease, enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type 1 started in 2005 and in the course of time, other enzymes were used for dealing with other types of MPS.
After establishment of the MPS Society, thank to the support and efforts extended by Dr. Mr. Davoudian in Sarem Hospital (the hospital that is directed by Dr. Mr. Shafeghati) and a number of his colleagues, certain number of the MPS affected-patients now are enjoying the support provided by the charity donors in supplying required medicine and drugs.
Mucopolysaccharidosis is a genetic disease caused by a mutation in a gene leading to deficiency of the lysosomal enzyme or break within several genes. Out of phenotypic symptoms of this disease, we can refer to enlargement of liver and spleen, corneal clouding, pigeon toes, umbilical hernia, inguinal hernia, deformation of bones in disease progression, heart and lung problems, hydrocephalus and Spinal stenosis (cervical region) causing movement disorders in the patients.
Presently Ms. Sara Noori is the president of the MPS Society.